A. Murray

CMRF44+ Dendritic Cells from Peripheral Blood Stem Cell Harvests of Patients with Myeloma as Potential Cellular Vectors for Idiotype Vaccination

D. Joshua, D. Hart, D. Sze, 2003, Leukemia & lymphoma.

B7+ T Cells in Myeloma: an Acquired Marker of Prior Chronic Antigen Presentation

D. Joshua, Ross D. Brown, D. Sze, 2004, Leukemia & lymphoma.

Dead or alive: immunogenicity of human melanoma cells when presented by dendritic cells.

I. Rennie, K. Sisley, A. Murray, 2000, Cancer research.

Either interleukin‐12 or interferon‐γ can correct the dendritic cell defect induced by transforming growth factor β1 in patients with myeloma

D. Joshua, Ross D. Brown, D. Hart, 2004 .

Phenotyping primitive plasma cells

D. Joshua, Ross D. Brown, B. Pope, 2002, British journal of haematology.

Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10.

D. Joshua, Ross D. Brown, D. Hart, 2001, Blood.

Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma.

D. Joshua, Ross D. Brown, D. Hart, 2004, British journal of haematology.